Rituximab improves interstitial lung disease in rheumatoid arthritis patients

M. Nieto Barbero (Madrid, Spain)

Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Session: The spectrum of CTDs: from pathogenesis to treatment
Session type: Thematic Poster
Number: 893
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Nieto Barbero (Madrid, Spain). Rituximab improves interstitial lung disease in rheumatoid arthritis patients. 893

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis
Source: Eur Respir J 2002; 20: Suppl. 38, 587s
Year: 2002

Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis
Source: Annual Congress 2004 - Fibrosing lung diseases
Year: 2004


Methotrexate and rheumatoid arthritis associated interstitial lung disease
Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020
Year: 2021



Interstitial lung disease in patients with rheumatoid arthritis
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008

Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis
Source: Eur Respir J 2004; 24 : 708
Year: 2004


Predicting outcomes in rheumatoid arthritis related interstitial lung disease
Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018
Year: 2019



Mortality and clinical features in rheumatoid arthritis and interstitial lung disease
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017

Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA)
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020


The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management
Year: 2018



Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020
Year: 2021



Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2016; 47: 588-596
Year: 2016



Pulmonary involvement in patients with rheumatoid arthritis
Source: Eur Respir J 2006; 28: Suppl. 50, 381s
Year: 2006

Risk factors of interstitial lung diseases in patients with rheumatoid arthritis.
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019

RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients
Source: Eur Respir J 2014; 44: 1082-1085
Year: 2014


Pulmonary disease associated with rheumatoid arthritis
Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Year: 2021

Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019


Cavitary nodules in rheumatoid arthritis patients and their prognosis
Source: International Congress 2018 – Sarcoidosis, interstitial lung diseases and various clinical problems
Year: 2018


Analysis of lung diseases associated with rheumatoid arthritis
Source: Eur Respir J 2006; 28: Suppl. 50, 307s
Year: 2006

Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2010; 35: 1206-1208
Year: 2010


The lung in rheumatoid arthritis: drugs versus underlying disease
Source: Annual Congress 2009 - Lung disease in rheumatoid arthritis treated with tumour necrosis factor inhibitors: a pulmonary perspective
Year: 2009